New Antimicrobial Agents for Use in the Intensive Care Unit

Infectious Disease Clinics of North America

Volumn 23, Issue 3, 2009, Pages 665-681

  Ritchie, David J ^a,b   Alexander, Bryan T ^a   Finnegan, Patrick M ^b  

^a BARNES JEWISH HOSPITAL   (United States)

^b ST LOUIS COLLEGE OF PHARMACY   (United States)

Author keywords

Antimicrobial resistance; Infection; Intensive care unit; Investigational agents; New antimicrobials

Indexed keywords

ANTIINFECTIVE AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFALEXIN; CEFEPIME; CEFTAROLINE FOSAMIL; CEFTAZIDIME; CEFTOBIPROLE MEDOCARIL; CEFTRIAXONE; CLINDAMYCIN; CYCLOSPORIN; DALBAVANCIN; FLUCONAZOLE; ICLAPRIM; ISAVUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; LINEZOLID; ORITAVANCIN; POSACONAZOLE; RIFAMPICIN; TACROLIMUS; TELAVANCIN; VANCOMYCIN; VORICONAZOLE; WARFARIN;

ACINETOBACTER BAUMANNII; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ASPERGILLOSIS; BACTERICIDAL ACTIVITY; BLOODSTREAM INFECTION; CANDIDEMIA; CATHETER INFECTION; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; CREATININE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG COMPETITION; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; ECG ABNORMALITY; ENTEROBACTER; ENTEROCOCCUS FAECIUM; ESOPHAGUS CANDIDIASIS; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEARING IMPAIRMENT; HEART DISEASE; HOSPITAL INFECTION; HUMAN; INJECTION SITE REACTION; INSOMNIA; INTENSIVE CARE UNIT; INVASIVE CANDIDIASIS; KLEBSIELLA PNEUMONIAE; MICROALBUMINURIA; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; ODOR; PNEUMONIA; PRURITUS; PSEUDOMONAS AERUGINOSA; QT PROLONGATION; REVIEW; RHINITIS; RHINOPHARYNGITIS; SIDE EFFECT; SINGLE DRUG DOSE; SKIN INFECTION; SLEEP DISORDER; STAPHYLOCOCCUS AUREUS; TASTE DISORDER; THROMBOCYTOPENIA; VENTILATOR ASSOCIATED PNEUMONIA; VESTIBULAR DISORDER; VOMITING;

ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; BACTERIAL INFECTIONS; HUMANS; INTENSIVE CARE UNITS; MYCOSES;

EID: 68049128263     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2009.04.010     Document Type: Review

References (117)

1. Kollef M.H., Sherman G., Ward S., et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115 (1999) 462-474
2. Ibrahim E.H., Sherman G., Ward S., et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 118 (2000) 146-155
3. Micek S.T., Lloyd A.E., Ritchie D.J., et al. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 49 4 (2005) 1306-1311
4. Schramm G.E., Johnson J.A., Doherty J.A., et al. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit Care Med 34 8 (2006) 2069-2074
5. Micek S.T., Kollef K.E., Reichley R.M., et al. Health care-associated pneumonia and community-acquired pneumonia: a single-center experience. Antimicrob Agents Chemother 51 10 (2007) 3568-3573
6. Morrell M., Fraser V.J., and Kollef M.H. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49 9 (2005) 3640-3645
7. Garey K.W., Rege M., Pai M.P., et al. Time to imitation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43 (2006) 25-31
8. Boucher H.W., Talbot G.H., Bradley J.S., et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48 (2009) 1-12
9. Sader H.S., Fritsche T.R., Kaniga K., et al. Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. Antimicrob Agents Chemother 49 8 (2005) 3501-3512
10. Mushtaq S., Warner M., Ge Y., et al. In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 60 (2007) 300-311
11. Ge Y., Biek D., Talbot G.H., et al. In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States. Antimicrob Agents Chemother 52 9 (2008) 3398-3407
12. Iizawa Y., Nagai J., Ishikawa T., et al. In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAL-599. J Infect Chemother 10 (2004) 146-156
13. Fenoll A., Aguilar L., Robledo O., et al. In vitro activity of ceftaroline against Streptococcus pneumoniae isolates exhibiting resistance to penicillin, amoxicillin, and cefotaxime. Antimicrob Agents Chemother 52 11 (2008) 4209-4210
14. McGee L., Biek D., Ge Y., et al. In vitro evaluation of the antimicrobial activity of ceftaroline against cephalosporin-resistant isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 53 2 (2009) 552-556
15. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: September 27-30, 2006.
16. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: September 27-30, 2006.
17. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: September 17-20, 2007.
18. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: September 27-30, 2006.
19. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: September 27-30, 2006.
20. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: September 27-30, 2006.
21. Talbot G.H., Thye D., Das A., et al. Phase 2 study of ceftaroline versus standard therapy in the treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother 51 10 (2007) 3612-3616
22. Available at: http://www.clinicaltrials.gov/ct2/results?term=ceftaroline. Accessed February 2, 2009.
23. Fritsche T.R., Sader H.S., and Jones R.N. Antimicrobial activity of ceftobiprole, a novel anti-methicillin-resistant Staphylococcus aureus cephalosporin, tested against contemporary pathogens: results from the SENTRY antimicrobial surveillance program (2005-2006). Diagn Microbiol Infect Dis 61 (2008) 86-95
24. Amsler K.M., Davies T.A., Shang W., et al. In vitro activity of ceftobiprole against pathogens from two phase 3 clinical trials of complicated skin and skin structure infections. Antimicrob Agents Chemother 52 9 (2008) 3418-3423
25. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25-28, 2008.
26. Hebeisen P., Heinze-Krauss I., Angehrn P., et al. In vitro and in vivo properties of Ro-63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob Agents Chemother 45 3 (2001) 825-836
27. Queenan A.M., Shang W., Kania M., et al. Interactions of ceftobiprole with ß-lactamases from molecular classes A to D. Antimicrob Agents Chemother 51 9 (2007) 3089-3095
28. Livermore D.M., Hope R., Brick G., et al. Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 62 suppl 2 (2008) ii41-ii51
29. Livermore D.M., Hope R., Brick G., et al. Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 62 suppl 2 (2008) ii55-63
30. Murthy B., and Schmitt-Hoffmann A. Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity. Clin Pharmacokinet 47 1 (2008) 21-33
31. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25-28, 2008.
32. Available at: http://www.clinicaltrials.gov/ct2/results?term=ceftobiprole. Acces-sed February 2, 2009.
33. Schmitt-Hoffmann, Roos B, Schleimer M, A et al. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother. 2004;48(7):2570-5.
34. Schmitt-Hoffmann A., Nyman L., Roos B., et al. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob Agents Chemother 48 7 (2004) 2576-2580
35. Lodise Jr. T.P., Pypstra R., Kahn J.B., et al. Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects. Antimicrob Agents Chemother 51 7 (2007) 2378-2387
36. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25-28, 2008.
37. Noel G.J., Strauss R.S., Amsler K., et al. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother 52 1 (2008) 37-44
38. Noel G.J., Bush K., Bagchi P., et al. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin structure infections. Clin Infect Dis 46 (2008) 647-655
39. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25-28, 2008.
40. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25-28, 2008.
41. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25-28, 2008.
42. Zhanel G.G., Trapp S., Gin A.S., et al. Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of gram-positive infections. Expert Rev Ant Infect Ther 6 1 (2008) 67-81
43. Van Bambeke F., Van Laethem Y.V., Courvalin P., et al. Glycopeptide antibiotics from conventional molecules to new derivatives. Drugs 64 9 (2004) 913-936
44. Malabarba A., and Goldstein B.P. Origin, structure, and activity in vitro and in vivo of dalbavancin. J Antimicrob Chemother 55 suppl S2 (2005) ii15-ii20
45. Candiani G., Abbondi M., Borgonovi M., et al. In-vitro and in-vivo antibacterial activity of BI 397, a new semi-synthetic glycopeptide antibiotic. J Antimicrob Chemother 44 (1999) 179-192
46. Van Bambeke F. Glycopeptides and glycodepsipeptides in clinical development: a comparative review of their antibacterial spectrum, pharmacokinetics, and clinical efficacy. Curr Opin Investig Drugs 7 8 (2006) 740-749
47. Goldstein B.P., Draghi D.C., Sheehan D.J., et al. Bactericidal activity and resistance development profiling of dalbavancin. Antimicrob Agents Chemother 51 4 (2007) 1150-1154
48. Chen A.Y., Zervos M.J., and Vazquez J.A. Dalbavancin: a novel antimicrobial. Int J Clin Pract 61 5 (2007) 853-863
49. Lin S.-W., Carver P.L., and DePestel D.D. Dalbavancin: a new option for the treatment of gram-positive infections. Ann Pharmacother 40 (2006) 449-460
50. Jauregui L.E., Babazadeh S., Seltzer E., et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin Infect Dis 41 (2005) 1407-1415
51. Seltzer E., Dorr M., Goldstein B.P., et al. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 37 (2003) 1298-1303
52. Raad I., Darouiche R., Vazquez J., et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis 40 (2005) 374-380
53. Leighton A., Gottlieb A., Dorr M., et al. Tolerability, pharmacokinetics, and serum bactericidal activity of intravenous dalbavancin in healthy volunteers. Antimicrob Agents Chemother 48 3 (2004) 940-945
54. Available at: http://mediaroom.pfizer.com/news/pfizer/20080909005943/en. Accessed January 6, 2009.
55. Mercier R.-C., and Hrebickova L. Oritavancin: a new avenue for resistant gram-positive bacteria. Expert Rev Anti Infect Ther 3 3 (2005) 325-332
56. Tenover F.C., Lancaster M.V., Hill B.C., et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 36 4 (1998) 1020-1027
57. Judice J.K., and Pace J.L. Semi-synthetic glycopeptide antibacterials. Bioorg Med Chem Lett 13 (2003) 4165-4168
58. th ICC. Munich: March 31-April 3, 2007.
59. Bhavnani S.M., Owen J.S., Loutit J.S., et al. Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis 50 (2004) 95-102
60. Van Bambeke F., Saffran J., Mingeot-Leclercq M.-P., et al. Mixed-lipid storage disorder induced in macrophages and fibroblasts by oritavancin (LY333328), a new glycopeptide antibiotic with exceptional cellular accumulation. Antimicrob Agents Chemother 49 5 (2005) 1695-1700
61. A study for patients with complicated skin and skin structure infections (SIMPLIFI). Available at: http://clinicaltrials.gov/ct2/show/NCT00514527?term=oritavancin&rank=1. Accessed February 1, 2009.
62. Loutit J.S., O'Riordan W., San Juan J., et al. Phase 2 trial comparing four regimens of oritavancin vs. comparator in the treatment of patients with S. aureus bacteraemia. (abstract P541). Clin Microbiol Infect 10 issue s3 (2004) 122
63. Kaatz G.W., Seo S.M., Aeschlimann J.R., et al. Efficacy of LY333328 against experimental methicillin-resistant Staphylococcus aureus endocarditis. Antimicrob Agents Chemother 42 4 (1998) 981-983
64. Lefort A., Saleh-Mghir A., Garry L., et al. Activity of LY333328 combined with gentamicin in vitro and in rabbit experimental endocarditis due to vancomycin-susceptible or -resistant Enterococcus faecalis. Antimicrob Agents Chemother 44 11 (2000) 3017-3020
65. Gerber J., Smirnov A., Wellmer A., et al. Activity of LY333328 in experimental meningitis caused by a Streptococcus pneumoniae strain susceptible to penicillin. Antimicrob Agents Chemother 45 7 (2001) 2169-2172
66. Cabellos C., Fernandez A., Maiques J.M., et al. Experimental study of LY333328 (oritavancin), alone and in combination, in therapy of cephalosporin-resistant pneumococcal meningitis. Antimicrob Agents Chemother 47 6 (2003) 1907-1911
67. Available at: http://www.investorcalendar.com/IC/GenRelease.asp?ID=138672. Accessed February 1, 2009.
68. Leonard S.N., and Rybak M.J. Telavancin: an antimicrobial with a multifunctional mechanism of action for the treatment of serious gram-positive infections. Pharmacotherapy 28 4 (2008) 458-468
69. Attwood R.J., and LaPlante K.L. Telavancin: a novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64 (2007) 2335-2348
70. King A., Phillips I., and Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against gram-positive bacteria. J Antimicrob Chemother 53 (2004) 797-803
71. Gander S., Kinnaird A., and Finch R. Telavancin: in vitro activity against staphylococci in a biofilm model. J Antimicrob Chemother 56 (2005) 337-343
72. Leuthner K.D., Cheung C.M., and Rybak M.J. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus. J Antimicrob Chemother 58 (2006) 338-343
73. Dunbar L.M., Tang D.M., and Manausa R.M. A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI). Ther Clin Risk Manag 4 1 (2008) 235-244
74. Available at: http://ir.theravance.com/ReleaseDetail.cfm?ReleaseID=279919. Accessed January 6, 2009.
75. Available at: http://ir.theravance.com/ReleaseDetail.cfm?ReleaseID=348983. Accessed January 24, 2009.
76. Schneider P., Hawser S., and Islam K. Iclaprim, a novel diaminopyrimidine with potent activity on trimethoprim sensitive and resistant bacteria. Bioorg Med Chem Lett 13 (2003) 4217-4221
77. Hawser S., Lociuro S., and Islam K. Dihydrofolate reductase inhibitors as antibacterial agents. Biochem Pharmacol 71 (2006) 941-948
78. Laue H., Weiss L., Bernardi A., et al. In vitro activity of the novel diaminopyrimidine, iclaprim, in combination with folate inhibitors and other antimicrobials with different mechanisms of action. J Antimicrob Chemother 60 (2007) 1391-1394
79. Bozdogan B., Esel D., Whitener C., et al. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical center. J Antimicrob Chemother 52 (2003) 864-868
80. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: September 17-20, 2007.
81. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: September 17-20, 2007.
82. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: September 17-20, 2007.
83. Hawser S, Lociuro S, Islam K. In vitro spectrum of activity of iclaprim against various Gram-positive and Gram-negative pathogens (poster CPLA-32). Presented at: The third International Symposium on Resistant Gram-positive Infections. Niagara-on-the-Lake, Ontario: October 9-11, 2006.
84. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: September 17-20, 2007.
85. Kohlhoff S.A., Roblin P.M., Reznik T., et al. In vitro activity of a novel diaminopyrimidine compound, iclaprim, against Chlamydia trachomatis and C. pneumoniae. Antimicrob Agents Chemother 48 5 (2004) 1885-1886
86. Morrissey I., and Hawser S. Activity of iclaprim against Legionella pneumophila. J Antimicrob Chemother 60 (2007) 905-906
87. Proctor R.A. Role of folate antagonists in the treatment of methicillin-resistant Staphylococcus aureus infection. Clin Infect Dis 46 (2008) 584-593
88. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco: September 27-30, 2006.
89. Food and Drug Administration (FDA). FDA briefing document for Anti-infective Drugs Advisory Committee Meeting, November 20, 2008 (Iclaprim for the treatment of complicated skin and skin structure infection). Available at: http://fda.gov/ohrms/dockets/ac/08/briefing/2008-4394b3-01-FDA.pdf. Accessed December 23, 2008.
90. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago: September 17-20, 2007.
91. Andrews J., Honeybourne D., Ashby J., et al. Concentrations in plasma, epithelial lining fluid, alveolar macrophages and bronchial mucosa after a single intravenous dose of 1.6 mg/kg of iclaprim (AR-100) in healthy men. J Antimicrob Chemother 60 (2007) 677-680
92. th Annual Meeting of the Infectious Diseases Society of America. San Diego: October 4-7, 2007.
93. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25-28, 2008.
94. Clinical efficacy of intravenous iclaprim versus vancomycin in the treatment of hospital-acquired, ventilator-associated, or health-care-associated pneumonia. http://www.clinicaltrials.gov/ct2/show/NCT00543608?term=iclaprim&rank=1. Accessed January 2, 2009.
95. Available at: http://www.clinicaltrials.gov/ct2/results?term=isavuconazole. Accessed January 2, 2009.
96. Seifert H., Aurbach U., Stefanik D., et al. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob Agents Chemother 51 5 (2007) 1818-1821
97. Guinea J., Pelaez T., Recio S., et al. In vitro activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 52 4 (2008) 1396-1400
98. Warn P.A., Sharp A., and Denning D.W. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J Antimicrob Chemother 57 (2006) 135-138
99. Illnait-Zaragozi M.-T., Martinez G.F., Curfs-Breuker I., et al. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob Agents Chemother 52 4 (2008) 1580-1582
100. Martin de la Escalera C., Aller A.I., Lopez-Oviedo E., et al. Activity of BAL 4815 against filamentous fungi. J Antimicrob Chemother 61 (2008) 1083-1086
101. Gonzalez G.M. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi. Med Mycol 47 1 (2009) 71-76
102. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25-28, 2008.
103. Schmitt-Hoffmann A., Roos B., Heep M., et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 50 1 (2006) 279-285
104. Schmitt-Hoffmann A., Roos B., Maares J., et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother 50 1 (2006) 286-293
105. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25-28, 2008.
106. Ohwada J., Tsukazaki M., Hayase T., et al. Design, synthesis and antifungal activity of a novel water soluble prodrug of antifungal triazole. Bioorg Med Chem Lett 13 (2003) 191-196
107. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25-28, 2008.
108. Warn P.A., Sharp A., Mosquera J., et al. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J Antimicrob Chemother 58 (2006) 1198-1207
109. Majithiya J., Sharp A., Parmar A., et al. Efficacy of isavuconazole, voriconazole, and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J Antimicrob Chemother 63 (2009) 161-166
110. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: December 16-19, 2005.
111. th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: October 25-28, 2008.
112. th Congress of the International Society for Human and Animal Mycology. Paris: June 26-29, 2006.
113. th Congress of the International Society for Human and Animal Mycology. Paris: June 26-29, 2006.
114. th Congress of the International Society for Human and Animal Mycology. Paris: June 26-29, 2006.
115. th Congress of the International Society for Human and Animal Mycology. Paris: June 26-29, 2006.
116. th Congress of the International Society for Human and Animal Mycology. Paris: June 26-29, 2006.
117. Pasqualetto A.C., and Denning D.W. New and emerging treatments for fungal infections. J Antimicrob Chemother 61 suppl. 1 (2008) i19-i30